Events preceding death among chikungunya virus infected patients: a systematic review.

Since its re-emergence in the late 1990s, there have been reports of Chikungunya fever (CHIK-F) presenting with severe or atypical findings. There is little knowledge regarding the clinical events leading to the death of patients with CHIK-F. This study aimed to systematically review the literature regarding CHIK-F and identify clinical features preceding death. We searched PubMed, Scopus, Embase, Lilacs, and IsiWeb for case-reports, case-series, or cohorts of CHIK-F reporting at least one death, up to December 2019. Fifty-seven reports were analyzed, including 2140 deaths. Data about specific clinical events that precede death are scarce. The central tendency of time between disease onset and death ranged from 2 days to 150 days. The most common clinical findings among decedents were fever (22.0%), arthralgia (15.7%), myalgia (10.7%), and headache (8.2%). Excluding pediatric populations, the reported central tendency of age among the decedents was 53 or older, with a non-weighted median of 67, ranging up to 80 years old. Authors mentioned organic dysfunction in 91.2% reports. Among all the 2140 decedents, the most common dysfunctions were cardiovascular (7.2%), respiratory (6.4%), neurological (5.4%), renal (4.2%), liver (3.0%), and hematological (1.3%) dysfunction. Exacerbation of previous diabetes (5.6%) or hypertension (6.9%) was mentioned as conditions preceding death. Currently, older age, primary neurological, cardiovascular, or respiratory dysfunction and a previous diagnosis of diabetes or hypertension are the main clinical events preceding death.

Events preceding death among chikungunya virus infected patients: a systematic review

Abstract Since its re-emergence in the late 1990s, there have been reports of Chikungunya fever (CHIK-F) presenting with severe or atypical findings. There is little knowledge regarding the clinical events leading to the death of patients with CHIK-F. This study aimed to systematically review the literature regarding CHIK-F and identify clinical features preceding death. We searched PubMed, Scopus, Embase, Lilacs, and IsiWeb for case-reports, case-series, or cohorts of CHIK-F reporting at least one death, up to December 2019. Fifty-seven reports were analyzed, including 2140 deaths. Data about specific clinical events that precede death are scarce. The central tendency of time between disease onset and death ranged from 2 days to 150 days. The most common clinical findings among decedents were fever (22.0%), arthralgia (15.7%), myalgia (10.7%), and headache (8.2%). Excluding pediatric populations, the reported central tendency of age among the decedents was 53 or older, with a non-weighted median of 67, ranging up to 80 years old. Authors mentioned organic dysfunction in 91.2% reports. Among all the 2140 decedents, the most common dysfunctions were cardiovascular (7.2%), respiratory (6.4%), neurological (5.4%), renal (4.2%), liver (3.0%), and hematological (1.3%) dysfunction. Exacerbation of previous diabetes (5.6%) or hypertension (6.9%) was mentioned as conditions preceding death. Currently, older age, primary neurological, cardiovascular, or respiratory dysfunction and a previous diagnosis of diabetes or hypertension are the main clinical events preceding death.

A saúde na Agenda 2030 de Desenvolvimento Sustentável na América Latina: quem está publicando? / Health in the Sustainable Development Agenda 2030 in Latin America: who is publishing? / La salud en la Agenda 2030 de Desarrollo Sostenible en América Latina: ¿Quién está publicando?

Este artigo apresenta um trabalho que consistiu no levantamento quantitativo das publicações sobre a Agenda 2030 de Desenvolvimento Sustentável na América Latina, ou que foram escritas por autores afiliados às instituições da região, focando no tema saúde. Foram realizadas buscas em bancos de dados, para o período entre janeiro de 2009 e maio de 2017, e encontradas 127 publicações voltadas para o Objetivo de Desenvolvimento Sustentável 3 ­ Boa Saúde e Bem-Estar. A maior parcela dos resultados (92%) é constituída de artigos científicos que foram descritos segundo o ano e veículo de publicação, instituições de filiação dos autores e sua localização. Quase a metade das publicações (47%) foi feita sem a participação de organizações latino-americanas e em apenas 30% dos casos o primeiro autor pertence a uma organização latino-americana. Esse quadro se torna mais nítido quando se observa a concentração da produção latinoamericana em torno de organizações brasileiras: a produção científica sobre as resoluções da Agenda 2030 em relação à saúde ainda está ausente em grande parte do território latino-americano.

This article presents a work that consisted of a quantitative research about publications on Agenda 2030 on Sustainable Development in Latin America, or written by authors affiliated with institutions in the region, focusing on health. A search using databases on the subject for the period between January 2009 and May 2017 was made, and 127 publications focusing on Sustainable Development Goal 3 ­ Good Health and Well-Being. The majority (92%) of the publications were scientific articles and were described in relation to the year and vehicle of publication, authors' affiliation institutions and their location. Almost half of the publications (47%) were made without the participation of Latin American organizations and only 30% of cases have the first author who belongs to a Latin American organization. This picture becomes clearer when we see the concentration of Latin American production at Brazilian organizations: scientific production onAgenda 2030 regarding health is still absent in much of the Latin American territory.

Este artículo presenta un trabajo que ha consistido en el levantamiento cuantitativo de las publicaciones sobre la Agenda 2030 en América Latina o que fueron escritas por autores afiliados a instituciones de la región con el foco en salud. Se realizaron búsquedas en bancos de datos para el período entre 2009 y mayo de 2017. Se encontraron 127 publicaciones sobre el Objetivos de desarrollo sostenible 3 ­ Salud y Bienestar. Constituyen la mayoría (92%) artículos científicos que fueron descritos según el año y el vehículo de publicación, las instituciones de filiación de los autores y su ubicación. En casi la mitad de las publicaciones (47%) no hubo participación de organizaciones latinoamericanas y solamente en 30% de los casos el primer autor pertenece a una organización latinoamericana. Este cuadro es más nítido cuando observada la concentración de la producción latinoamericana en organizaciones brasileñas: La producción científica sobrela Agenda 2030 en el área de la salud todavía está ausente en gran parte de la América Latina.

Severe infection increases cardiovascular risk among HIV-infected individuals.

BACKGROUND: The identification and management of cardiovascular risk factors became a major clinical issue among HIV-infected individuals in the post-cART era. As in the past decades the link between acute infections and cardiovascular diseases became clear in the general population, we sorted to investigate the role of severe infections on incident cardiovascular diseases (CVDs) among HIV-infected individuals. METHODS: HIV-infected individuals aged ≥18 years, with no history of CVD were followed from January 2000 to December 2013 until the occurrence of the first CVD event, death or end of study, whichever occurred first. To explore the effect of severe infections on the incidence of CVD we used extended Cox regression models and stratified post-hospitalization follow-up time into three periods: < 3 months, 3-12 months and > 12 months post discharge. RESULTS: One hundred-eighty four persons from 3384 HIV-infected individuals developed incident CVD events during the follow-up (incidence rate = 11.10/1000 PY (95%CI: 9.60-12.82)). Risk of an incident CVD was 4-fold higher at < 3 months post-hospitalization for severe infections (adjusted hazard ratio [aHR], 4.52; 95% confidence interval [CI] 2.46-8.30), after adjusting for sociodemographic and clinical factors as well as comorbidities. This risk remained significant up to one year (3-12 months post hospital discharge aHR 2.39, 95% CI 1.30-4.38). Additionally, non-white race/ethnicity (aHR 1.49, 95% CI 1.10-2.02), age ≥ 60 years (aHR 2.01, 95% CI 1.01-3.97) and hypertension (aHR 1.90, 95% CI 1.38-2.60) were associated with an increased risk of CVD events. High CD4 (≥ 500 cells/mm3: aHR 0.41, 95% CI 0.27-0.62) and cART use (aHR 0.21, 95% CI 0.14-0.31) reduced the risk of CVD events. CONCLUSIONS: We provide evidence for a time-dependent association between severe infection and incident cardiovascular disease in HIV-infected individuals. cART use, and high CD4 count were significantly associated with reduced hazards of CVD.

Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil.

OBJECTIVES: To assess the temporal trends in incidence of AIDS-defining opportunistic illnesses in an urban cohort of a middle-income country. METHODS: HIV infected patients aged ≥ 18 years at cohort entry were included in this analysis. We calculated incidence rates per 1000 persons-years of observation for the first opportunistic illness presented after cohort enrollment, from 1987 to 2012. Trends for overall and specific opportunistic illnesses were tested and incidence rate ratios for the most recent calendar period were calculated as the ratio between the incidence rate observed in the most recent period of the study (2009-2012) and the incidence rate observed in first period of the study (1987-1990). RESULTS: Overall, 3378 patients were included in this analysis; of which 1119 (33%) patients presented an opportunistic illness during follow up. Incidence rates of all opportunistic illnesses decreased over time, and the overall opportunistic illness incidence rates fell from 295.4/1000 persons-years in 1987-1990 to 34.6/1000 persons-years in 2009-2012. Tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jirovecii pneumonia were the most incident opportunistic illnesses in the cohort. Tuberculosis had the highest incidence rate in the study period. The peak in tuberculosis incidence occurred in 1991-1993 (80.8/1000 persons-years). Cerebral toxoplasmosis was the third most incident opportunistic illness in the study, with a peak of incidence of 43.6/1000 persons-year in 1987-1990. CONCLUSIONS: All opportunistic illnesses incidence rates decreased over the years but they still occur in an unacceptable frequency. Tuberculosis co-infection among HIV-infected persists as an important challenge for health care professionals and policy makers in our setting. Impressively high rates of cerebral toxoplasmosis were found suggesting that its incidence among HIV-infected is linked to the high prevalence of Toxoplasma gondii infection in the general population.

Sepse e HIV: efeitos na resposta inflamatória e prognóstico

A infecção pelo HIV é um problema de saúde pública global, sendo estimadas 33,4 milhões de pessoas vivendo infectadas no final de 2008 (UNAIDS, 2009). No Brasil, desde o início da epidemia até junho de 2010, foram registrados 592.914 casos de síndrome da imunodeficiência adquirida (SIDA/AIDS) pelo Ministério da Saúde (Ministério da Saúde, 2010). Em 1996, com o início da terapia HAART (Highly Active Antiretroviral Therapy) ocorreu uma importante melhora do prognóstico, diminuição da letalidade, aumento na sobrevida dos pacientes HIV positivo, gerando uma mudança nas causas de internação. A incidência sepse na população geral vem aumentando, assim como na população HIV positivo. Foi demonstrado que a presença de sepse e sepse grave foi determinante na mortalidade da população HIV positivo. Acompanhamos prospectivamente pacientes HIV/SIDA, com critérios de sepse de acordo com a Conferência de Consenso da American College of Chest Physicians/ Society of Critical Care Medicine (ACCP/SCCM), onde as características clínicas e o prognóstico destes pacientes foram sistematicamente avaliados, bem como o padrão de resposta inflamatória frente a um quadro infeccioso graveForam incluídos 30 pacientes, com mediana da idade de 35 anos (IQ 18-58), com predomínio do sexo masculino (73 por cento). A mortalidade hospitalar observada foi de 50 por cento. A contagem de CD4 positivo deste pacientes foi 72 (mediana, IQ 16-190), e a carga viral de 33.028 cópias (mediana, IQ 2877-434.237) O principal sítio de infecção foi pulmonar, em 23 pacientes (76,7 por cento ). 10 pacientes apresentaram bacteremia confirmada (33 por cento). O principal agente identificado foi Mycobacterium tuberculosis (22 por cento). Não observamos nenhum parâmetro clínico nos pacientes HIV positivo com sepse que estivesse associado com prognóstico. As concentrações plasmáticas de cortisol, IL-6, IL-10 e G-CSF foram significativamente maiores entre os pacientes não sobreviventes em relação aos sobreviventes. Quando comparamos os pacientes HIV positivo sépticos com pacientes sépticos não-HIV a taxa de mortalidade não foi diferente. A mediana do SOFA nos pacientes sépticos HIV positivo e não-HIV foram 8 e 10 pontos, respectivamente; a mediana do SAPS II em ambos os grupos foi 55 pontos. Níveis de citocinas plasmáticas detectadas pelo sistema multiplex de pacientes sépticos (HIV positivo e não-HIV) no primeiro dia da sepse não apresentaram diferença significativa entre os gruposComparando a concentração plasmática do MIF en pacientes sépticos (HIV positivo vs não-HIV), estavam maiores nos pacientes HIV positivo (2,730 vs 0,7700 ng/mL, P=0,01), e os níveis de cortisol encontrados eram menores no grupo HIV positivo. Cortisol, IL-6, IL-10, e G-CSF são possíveis biomarcadores de prognóstico na população HIV+ com diagnóstico de sepse. Pacientes HIV+ com sepse apresentam concentrações plasmáticas de MIF maiores que a população geral, o que pode estar relacionado com a própria infecção pelo HIV, embora este achado deva ser melhor investigado. Embora os pacientes HIV positivo tenham um comprometimento da imunidade celular, o padrão de ativação da imunidade inata frente a um quadro infeccoso grave, em especial da produção de citocinas, não difere tanto da população não-HIV.